<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36753">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01821521</url>
  </required_header>
  <id_info>
    <org_study_id>AGSPT_L20PK</org_study_id>
    <nct_id>NCT01821521</nct_id>
  </id_info>
  <brief_title>Investigate a Pharmacokinetics Between S-pantoprazole 20mg and Pantoprazole 40mg in Healthy Male Subjects</brief_title>
  <acronym>S-Pantoprazole</acronym>
  <official_title>A Randomized, Open Label, Single-dose, 2x2 Crossover Study to Investigate a Pharmacokinetics Between S-pantoprazole 20mg and Pantoprazole 40mg in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahn-Gook Pharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ahn-Gook Pharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary object : Evaluate pharmacokinetic property administered S-pantoprazole 20mg and
      Pantoprazole 40mg in healthy male subjects

      Secondary object : Evaluate safety administered S-pantoprazole 20mg and Pantoprazole 40mg in
      healthy male subjects
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2β</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Healthy Male Subjects</condition>
  <arm_group>
    <arm_group_label>AGSPT_L20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet, q.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pantoloc 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tablet, q.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGSPT_L20</intervention_name>
    <arm_group_label>AGSPT_L20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoloc 40mg</intervention_name>
    <arm_group_label>Pantoloc 40mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult healthy males 20 to 45 years at screening.

          -  BMI : 19kg/m2 ~ 26kg/m2

          -  Blood Pressure : &quot;140 &gt; sitting SBP ≥ 90mmHg, 90 &gt; sitting DBP ≥ 60mmHg&quot;

        Exclusion Criteria:

          -  Have history of significant hepatic, renal, gastrointestinal, pulmonary,
             musculoskeletal, endocrine, neuropsychiatric, hematologic, cardiovascular diseases

          -  Have a gastrointestinal disease(ex : Crohn's disease, gastrointestinal ulcer)or
             surgery(except for Appendectomy, Hernia repair) affected the absorption of
             medications

          -  Have history of GERD, Gastric ulcer, Duodenal ulcer

          -  Hypersensitivity reactions to drugs or clinically significant hypersensitivity
             reactions in the history of benzimidazole(ex:pantoprazole, NSAID, antibiotic)

          -  Have a history of drug abuse

          -  Unusual diet affected the absorption, distribution, metabolism, excretion of
             medications

          -  Subject who treated with any investigational drugs within 90 days before the
             administration of investigational drug

          -  Subject who takes inhibitors and inducers of drug metabolizing enzyme (Barbiturates
             etc.) within 30days

          -  Previously donate whole blood within 60 days or component blood within 30 days or
             transfusion within 30 days

          -  Subject who have taken habitually caffeine (caffeine &gt; 5 units/day)

          -  Subject who have drunken habitually (alcohol &gt; 21 units/week, 1 unit = pure alcohol
             10ml)or who are unable to quit drinking during this study or smoker

          -  Subjects deemed ineligible by investigator based on other reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sang-Young Yoon</last_name>
    <phone>+82-2-3289-4257</phone>
    <email>agcntechpp@ahn-gook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheul-Hun Seong</last_name>
    <phone>+82-2-3289-4284</phone>
    <email>agcntechpp@ahn-gook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheul-Hun Seong</last_name>
      <phone>+82-2-3289-4284</phone>
    </contact>
    <investigator>
      <last_name>Kyun-Seop Bae, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 29, 2013</lastchanged_date>
  <firstreceived_date>March 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
